These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 10354266

  • 21. Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women.
    Need AG, Horowitz M, Morris HA, Nordin BC.
    Am J Clin Nutr; 2000 Jun; 71(6):1577-81. PubMed ID: 10837301
    [Abstract] [Full Text] [Related]

  • 22. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 23. Vitamin D deficiency and associated factors in hemodialysis patients.
    Jean G, Charra B, Chazot C.
    J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
    [Abstract] [Full Text] [Related]

  • 24. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism.
    Costa AF, dos Reis LM, Ribeiro MC, Moysés RM, Jorgetti V.
    Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644
    [Abstract] [Full Text] [Related]

  • 25. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
    Coen G, Mantella D, Manni M, Balducci A, Nofroni I, Sardella D, Ballanti P, Bonucci E.
    Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
    [Abstract] [Full Text] [Related]

  • 26. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [Abstract] [Full Text] [Related]

  • 27. Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy.
    Bellazzi R, Romanini D, Bacchella L, Nai M, Aprile C, Santagostino M, De Vincenzi A.
    Nephron; 1991 Jan; 57(3):273-82. PubMed ID: 2017266
    [Abstract] [Full Text] [Related]

  • 28. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
    Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C.
    Nephron Clin Pract; 2008 Jan; 110(1):c58-65. PubMed ID: 18724068
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients.
    Richter A, Kuhlmann MK, Seibert E, Kotanko P, Levin NW, Handelman GJ.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2058-63. PubMed ID: 18353890
    [Abstract] [Full Text] [Related]

  • 31. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF, Arora N, Torres C, Ramdeen G, Schaeffer-Pautz A, Moles K.
    Adv Perit Dial; 2000 Jun; 16():303-7. PubMed ID: 11045316
    [Abstract] [Full Text] [Related]

  • 32. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study.
    Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L.
    Eur J Endocrinol; 2006 Aug; 155(2):237-44. PubMed ID: 16868136
    [Abstract] [Full Text] [Related]

  • 33. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
    Ben Hamida F, Ghazali A, Boudzernidj M, Amar M, Morinière P, Westeel P, Fournier A.
    Ann Endocrinol (Paris); 1994 Aug; 55(5):147-58. PubMed ID: 7857079
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Low bone turnover in patients with renal failure.
    Couttenye MM, D'Haese PC, Verschoren WJ, Behets GJ, Schrooten I, De Broe ME.
    Kidney Int Suppl; 1999 Dec; 73():S70-6. PubMed ID: 10633468
    [Abstract] [Full Text] [Related]

  • 37. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly.
    Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3086-90. PubMed ID: 11443171
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
    Malberti F, Surian M, Cosci P.
    Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
    [Abstract] [Full Text] [Related]

  • 40. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
    Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Jimenez A, Torres A, Felsenfeld AJ.
    Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.